May 28 - Shares of the company that until recently operated as Hoth Therapeutics jumped sharply in premarket activity on Thursday, rising by about 60 percent as it started trading under its new Rocket One name and ticker for the first time.
The rebranding and corporate restructuring were disclosed earlier this month, with the firm saying it will pivot from its prior biotech identity to pursue opportunities in AI infrastructure, semiconductor technologies and AI computing. Management also announced plans to develop space-based AI systems intended for use on satellites, while keeping the company’s existing biotech programs operating within a separate subsidiary.
Hoth had been advancing an experimental skin treatment drug but had yet to record any revenue from operations. The company reported a loss of $0.17 per share in the March quarter, according to its reported results.
The move into space-focused AI comes amid heightened investor attention to the space sector. The company statement referenced a wave of interest that followed Elon Musk’s rocket company SpaceX filing for an initial public offering last week, a development that coincided with rallies in smaller space-related stocks including Rocket Lab and Intuitive Machines.
AI has already been a powerful theme on markets for some time, and recent weeks have seen several small firms with legacy businesses unrelated to AI announce sudden pivots toward AI branding. Examples cited include footwear maker Allbirds and social media company Myseum, which last month adopted AI-related identities and experienced sharp increases in their share prices. Market observers have pointed to these moves as evidence of investor enthusiasm for AI-related names, which can become a magnet for capital and offer companies a path to fundraising even when their legacy operations are not connected to the technology.
In intraday activity, the company’s stock was up 58.1 percent to $2.15 on Thursday, and its market capitalization at the prior close stood at just over $26 million.
What this means
The company’s rebrand repositions a small-cap, pre-revenue biotech firm as a player seeking to combine AI computing and semiconductor ambitions with space systems development. That repositioning has been met with strong investor buying in the near term, but the firm’s financial profile remains unchanged by the announcement - it remains pre-revenue and reported a quarterly per-share loss.
Market context
- Smaller space stocks saw gains alongside the broader surge in interest following SpaceX’s IPO filing, with tickers such as RKLB and Intuitive Machines among those that rallied.
- Recent rebrands toward AI-related identities by companies with unrelated legacy businesses have triggered notable share price jumps, illustrating the strong investor appetite for AI exposure.